Explore All Access
Check if your research matches the topics covered in Lung Cancer: Targets and Therapy?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Lung Cancer: Targets and Therapy : Impact Factor & More
eISSN: 1179-2728pISSN: 1179-2728
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Lung Cancer: Targets and Therapy Key Metrics
CiteScore 
6.5
SNIP
1.15
Lung Cancer: Targets and Therapy Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
One subscription packed with expert publication services and AI tools to get you published
Brought to you by 
Journal Selection Service
Benefit from our experts' recommendations of 3-5 best-suited journals, accompanied by a detailed Journal Selection report explaining the choices. Make informed decisions.
Journal Submission Service
Streamline your submission process with meticulous manuscript formatting to meet journal guidelines, crafting a tailored cover letter for the editor, and hassle-free account creation and submission
Bundle of AI tools for your research needs
Journal Finder, Paperpal, R Discovery, MindTheGraph and more
Planning to publish in Lung Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Lung Cancer: Targets and Therapy
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
- 1 Mar 2024
- Lung Cancer (Auckland, N.Z.)
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
- 1 Feb 2024
- Lung Cancer (Auckland, N.Z.)
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach.
- 1 Feb 2024
- Lung Cancer (Auckland, N.Z.)
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact.
- 1 Jan 2024
- Lung Cancer (Auckland, N.Z.)
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer.
- 1 Nov 2023
- Lung Cancer (Auckland, N.Z.)
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.
- 1 Oct 2023
- Lung Cancer (Auckland, N.Z.)
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
- 1 Mar 2024
- Lung Cancer (Auckland, N.Z.)
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
- 1 Feb 2024
- Lung Cancer (Auckland, N.Z.)
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach.
- 1 Feb 2024
- Lung Cancer (Auckland, N.Z.)
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact.
- 1 Jan 2024
- Lung Cancer (Auckland, N.Z.)
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer.
- 1 Nov 2023
- Lung Cancer (Auckland, N.Z.)
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.
- 1 Oct 2023
- Lung Cancer (Auckland, N.Z.)
FAQs on Lung Cancer: Targets and Therapy
How long has Lung Cancer: Targets and Therapy been actively publishing? 
Lung Cancer: Targets and Therapy has been in operation since 2008 till date.
What is the publishing frequency of Lung Cancer: Targets and Therapy?
Lung Cancer: Targets and Therapy published with a Continuous publication frequency.
How many articles did Lung Cancer: Targets and Therapy publish last year?
In 2023, Lung Cancer: Targets and Therapy publsihed 12 articles.
What is the eISSN & pISSN for Lung Cancer: Targets and Therapy?
For Lung Cancer: Targets and Therapy, eISSN is 1179-2728 and pISSN is 1179-2728.
What is Citescore for Lung Cancer: Targets and Therapy?
Citescore for Lung Cancer: Targets and Therapy is 6.5.
What is SNIP score for Lung Cancer: Targets and Therapy?
SNIP score for Lung Cancer: Targets and Therapy is 1.15.
Who is the publisher of Lung Cancer: Targets and Therapy?
DOVE MEDICAL PRESS LTD is the publisher of Lung Cancer: Targets and Therapy.